Abstract
Hypertriglyceridemia is a common metabolic disorder which is mostly associated with other components of so-called atherogenic dyslipidemia, in particular with HDL-cholesterol reduction. Both experimental and epidemiological studies show that pathogenetic effects of hypertriglyceridemia are prevailingly indirect – they are intermediated by an increased production of "small dense" LDL particles and remnant particles and by a reduced concentration of HDL-cholesterol.
Therefore, hypertriglyceridemia primarily marks atherogenic changes of various lipoprotein particles and often also the occurrence of other components of the metabolic syndrome. The basis of hypertriglyceridemia treatment are dietary and regimen measures; if their efficacy is insufficient, the administration of fibrates or niacin can be considered.